Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy

Karen M. Gil, Stephanie L. Pugh, Ann H. Klopp, Anamaria R. Yeung, Lari Wenzel, Shannon N. Westin, David K. Gaffney, William Small, Spencer Thompson, Desiree E. Doncals, Guilherme H.C. Cantuaria, Brian P. Yaremko, Amy Chang, Vijayananda Kundapur, Dasarahally S. Mohan, Michael L. Haas, Yong Bae Kim, Catherine Lowrie Ferguson, Snehal Deshmukh, Lisa A. KachnicDeborah W. Bruner

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Objective: Women with endometrial or cervical cancer at risk for recurrence receive postoperative radiation therapy (RT). A patient reported outcomes (PRO) instrument to assess bowel and urinary toxicities is the Expanded Prostate Cancer Index Composite (EPIC), which has been validated in men with prostate cancer. As this instrument specifically measures bowel toxicity and the degree to which this is a problem, it was used in NRG Oncology/RTOG 1203 to compare intensity modulated RT (IMRT) to standard RT. This paper reports on the expanded validation of EPIC for use in women receiving pelvic RT. Methods: In addition to the EPIC bowel domain, urinary toxicity (EPIC urinary domain), patient reported bowel toxicities (PRO-CTCAE) and quality of life (Functional Assessment of Cancer Therapy (FACT)) were completed before, during and after treatment. Sensitivity, reliability and concurrent validity were assessed. Results: Mean bowel and urinary scores among 278 women enrolled were significantly worse during treatment and differed between groups. Acceptable to good reliability for bowel and urinary domain scores were obtained at all time points with the exception of one at baseline. Correlations between function and bother scores within the bowel and urinary domains were consistently stronger than those across domains. Correlations between bowel domain scores and PRO-CTCAE during treatment were stronger than those with the FACT. Conclusion: Correlations within and among the instruments indicate EPIC bowel and urinary domains are measuring conceptually discrete components of health. These EPIC domains are valid, reliable and sensitive instruments to measure PRO among women undergoing pelvic radiation.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalGynecologic Oncology
Volume154
Issue number1
DOIs
StatePublished - Jul 2019

Keywords

  • Bowel and urinary toxicity
  • Cervical and endometrial cancer
  • Patient reported outcomes
  • Pelvic radiation

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy'. Together they form a unique fingerprint.

  • Cite this

    Gil, K. M., Pugh, S. L., Klopp, A. H., Yeung, A. R., Wenzel, L., Westin, S. N., Gaffney, D. K., Small, W., Thompson, S., Doncals, D. E., Cantuaria, G. H. C., Yaremko, B. P., Chang, A., Kundapur, V., Mohan, D. S., Haas, M. L., Kim, Y. B., Ferguson, C. L., Deshmukh, S., ... Bruner, D. W. (2019). Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy. Gynecologic Oncology, 154(1), 183-188. https://doi.org/10.1016/j.ygyno.2019.04.682